Laparoscopic partial nephrectomy and percutaneous cryoablation for cT1 renal tumors are associated with similar 5-year rates of metastasis-free and overall and cancer-specific survival.
Atezolizumab plus cabozantinib was tolerable and demonstrated antitumor activity in patients with treatment-naïve, advanced ccRCC, according to a phase 1b study.
Gene signatures were identified as potential predictive biomarkers for outcomes with nivolumab among patients with advanced ccRCC in an analysis of the NIVOREN GETUG-AFU 26 trial.
Treatment of patients with aRCC who are ineligible for nephrectomy with nivolumab plus ipilimumab improved outcomes compared with sunitinib, in a post hoc analysis of CheckMate 214.
Compared with sunitinib alone, nivolumab plus cabozantinib therapy was associated with a 49% decreased risk for progression and 40% decreased risk for death.
